Form 4: Ironwood Pharmaceuticals Insider Stock Transaction

Ronald Silver, a Principal Financial and Accounting Officer at Ironwood Pharmaceuticals, reported a transaction involving 25,000 shares of common stock.

Summary

• Ronald Silver, identified as Principal Financial Officer and Principal Accounting Officer, reported a transaction on May 19, 2026.
• The transaction involved the acquisition of 25,000 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Mr. Silver beneficially owns 441,570 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider stock acquisition without immediate implications for the company's financial performance or strategic direction.

Positives

• Acquisition of 25,000 shares of common stock by a key executive.
• The executive's beneficial ownership remains substantial at 441,570 shares.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal strategic shifts, but they provide transparency into executive holdings.

Key Dates

Keywords

Form 4, Insider Trading, SEC Filing, Ironwood Pharmaceuticals, Common Stock, Beneficial Ownership, Ronald Silver